Press Room
September 6, 2006
Cognis at the 2006 CPhI show: High-purity excipients for the pharmaceutical industry
At this year’s CPhI show, to be held in Paris, France from October 3 to 5, Cognis’ Pharmaceuticals & Healthcare business unit will be exhibiting its range of natural-source building blocks, excipients and drug delivery agents for the pharmaceutical industry. One of the products that will be on show at the booth is the Chitopharm® excipient, a polysaccharide that accelerates the healing of flesh wounds. Cognis recently received US Drug Master File (type IV) for its Chitopharm range.
The regulatory burden on the pharmaceutical industry has steadily increased in recent years. At the same time, consumer expectations in terms of product quality have also risen. Chitopharm represents one of the few natural cationic polymers available, and its non-toxicity and biodegradability have enabled it to become well established in the market. Because it contains exceptionally low levels of endotoxins and heavy metals, it is suitable for a broad range of medical applications, including dermatological treatments, tissue engineering, cell culture and wound dressings. Cognis has successfully applied for US drug master files for Chitopharm, meaning that it is approved for use by Cognis customers as a pharmaceutical excipient.
Clear focus on segments offering high growth potential
In order to comply with the stricter requirements of regulators and consumers, Cognis has invested heavily in its Pharmaceutical & Healthcare business, enlarging its product range and implementing state-of-the-art manufacturing processes. A significant number of naturally derived products have already been brought to market and are used by the pharmaceutical industry as building blocks, excipients and drug delivery agents. Dr. Jochen Seifert, Global Product Line Manager Pharmaceuticals & Healthcare: “Our customers demand outstanding performance, and are looking for the very best ingredients to use in their products. By offering consistently high product quality, reliable availability and the highest standards of customer service, we help them succeed in their markets. Chitopharm is merely one example of the many high-grade products that we will be exhibiting at this year’s CPhI show.”
About Cognis
Cognis is a worldwide supplier of innovative specialty chemicals and nutritional ingredients, with a particular focus on the areas of wellness and sustainability. The company employs about 8,000 people, and it operates production sites and service centers in 30 countries. Cognis has dedicated its activities to a high level of sustainability and delivers natural source raw materials and ingredients for food, nutrition and healthcare markets, and the cosmetics, detergents and cleaners industries. Another main focus is on products for a number of other industries, such as coatings and inks, lubricants, textiles, as well as agriculture and mining. The company holds a 50-percent stake in the joint venture Cognis Oleochemicals, one of the world’s leading manufacturers of oleochemicals.
Cognis is owned by private equity funds advised by Permira, GS Capital Partners, and SV Life Sciences. In 2005, Cognis recorded sales of 3.18 billion euros and an Adjusted EBITDA (earnings before interest, income taxes, depreciation, amortization and exceptional items) of 356 million euros.
Contact
Andrea Pitrella, Marketing Manager
Pharmaceuticals & Healthcare
Cognis Deutschland GmbH & Co. KG
Phone: +49-2173-4995-128
E-mail: andrea.pitrella@cognis.com
pharmaceuticals@cognis.com
Internet: www.cognis.com
www.pharmaline.com
Dr. Claudia Scholz
Research Platform Manager
Cognis Deutschland GmbH & Co. KG
Phone: +49-30-843-127-71
E-mail: claudia.scholz@cognis.com
Internet: www.cognis.com
Raquel Ark, Corporate Communications Manager
Cognis Deutschland GmbH & Co. KG
Phone: +49-2173-4995-464
E-mail: raquel.ark@cognis.com
Internet: www.cognis.com